Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. clinical trials

A subsidiary of Huadong Medicine Co., Ltd.

The registry lists 50 studies whose lead sponsor is Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. 38 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 1, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 50. All Huadong Medicine Co., Ltd. studies →

• A Study of HDM2017 Combination Therapy in Advanced Colorectal CancerRecruitingNCT07805551Phase 1/2

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) TherapyNot yet recruitingNCT07794397Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) TherapyNot yet recruitingNCT07787260Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic DermatitisNot yet recruitingNCT07683806Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell LymphomaNot yet recruitingNCT07697339Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM2020 in Patients With Advanced Sq-NSCLCRecruitingNCT07638891Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal CancerNot yet recruitingNCT07621159Phase 1/2

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy SubjectsRecruitingNCT07594847Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy ParticipantsNot yet recruitingNCT07559240Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM2024 in Participants With Advanced Solid TumorsRecruitingNCT07539285Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without DiabetesRecruitingNCT07521631Phase 2

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and DigoxinNot yet recruitingNCT07502001Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorNot yet recruitingNCT07417306Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneRecruitingNCT07394114Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM2006 in Patients With Advanced Solid TumorRecruitingNCT07377591Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and WarfarinRecruitingNCT07331389Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without DiabetesRecruitingNCT07279194Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Phase 1 Study of HDM2017 in Advanced Solid TumorsRecruitingNCT07274085Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic ControlRecruitingNCT07244003Phase 4

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseaseNot yet recruitingNCT07116928Phase 4

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes MellitusRecruitingNCT06886126Phase 2

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes MellitusRecruitingNCT07193459Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminRecruitingNCT07109700Phase 2

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell LymphomaRecruitingNCT07124936Phase 1/2

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM2012 in Patients With Advanced Solid TumorRecruitingNCT07100249Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM2020 in Patients With Advanced Solid TumorsRecruitingNCT07098052Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes MellitusRecruitingNCT07082114Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese PatientsRecruitingNCT07036172Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM2005 in Patients With Advanced Solid TumorRecruitingNCT07004296Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic ImpairementRecruitingNCT06985615Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese AdultsNot yet recruitingNCT06885021Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid TumorRecruitingNCT06615193Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy SubjectsNot yet recruitingNCT06608329Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.Not yet recruitingNCT06601517Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy SubjectsRecruitingNCT06576401Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• HDM1002 Tablets in Chinese Overweight and Obese Adult SubjectsNot yet recruitingNCT06520540Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese AdultsNot yet recruitingNCT06500299Phase 2

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Pharmacokinetic Study of HDM1005 Injection at Different Injection SitesActive, not recruitingNCT07828197Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis SubjectsCompletedNCT07357831Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Phase Ib Clinical Study of HDM1005 InjectionCompletedNCT06637020Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 StudyCompletedNCT06648772Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Phase Ia Clinical Study of HDM1005 InjectionCompletedNCT06640647Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Efficacy and Safety of Roflumilast Cream in Subjects With Atopic DermatitisCompletedNCT06631170Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.CompletedNCT06634927Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 DiabetesCompletedNCT06739044Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes MellitusCompletedNCT06481085Phase 2

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy SubjectsStatus unknownNCT06562088Phase 1

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese ParticipantsCompletedNCT05943977Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian CancerStatus unknownNCT05622890Phase 3

  Sponsor listed in the registry: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.